[1]徐德强.不同剂量糖皮质激素治疗类风湿关节炎的临床疗效及安全性[J].医学信息,2023,36(08):143-146.[doi:10.3969/j.issn.1006-1959.2023.08.031]
　XU De-qiang.Clinical Efficacy and Safety of Different Doses of Glucocorticoid in the Treatment of Rheumatoid Arthritis[J].Journal of Medical Information,2023,36(08):143-146.[doi:10.3969/j.issn.1006-1959.2023.08.031]
点击复制

不同剂量糖皮质激素治疗类风湿关节炎的临床疗效及安全性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年08期
页码:
143-146
栏目:
论著
出版日期:
2023-04-15

文章信息/Info

Title:
Clinical Efficacy and Safety of Different Doses of Glucocorticoid in the Treatment of Rheumatoid Arthritis
文章编号:
1006-1959（2023）08-0143-04
作者:
徐德强
（黄家驷医院内分泌科，江西 玉山 334700）
Author(s):
XU De-qiang
(Department of Endocrinology,Huangjiasi Hospital,Yushan 334700,Jiangxi,China)
关键词:
糖皮质激素; 类风湿关节炎; 用药剂量; 关节活动度
Keywords:
Glucocorticoids; Rheumatoid arthritis; Drug dosage; Joint activity
分类号:
R593.22
DOI:
10.3969/j.issn.1006-1959.2023.08.031
文献标志码:
A
摘要:
目的 探讨不同剂量糖皮质激素治疗类风湿关节炎（RA）的临床疗效及安全性。方法 选取2020年2月-2022年1月黄家驷医院收治的60例RA患者，采用随机数字表法分为大剂量组（30例）与小剂量组（30例）。两组患者均给予糖皮质激素（泼尼松）治疗，大剂量组用药剂量为7.5~10 mg/d，小剂量组用药剂量＜7.5 mg/d。比较两组疼痛评估量表（RAPS）评分、晨僵时间、实验室指标[类风湿因子（RF）、红细胞沉降率（ESR）、C-反应蛋白（CRP）]、关节症状[压痛关节数目、肿胀关节数目、28个关节疾病活动度评分（DAS28）]、临床疗效及不良反应。结果 大剂量组RAPS评分、晨僵时间少于小剂量组（P＜0.05）；大剂量组RF、ESR、CRP水平低于小剂量组（P＜0.05）；大剂量组压痛及肿胀关节数目、DAS28评分均小于小剂量组（P＜0.05）；大剂量组临床缓解率高于小剂量组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 大剂量（7.5~10 mg/d）糖皮质激素治疗RA的效果更佳，其对患者疼痛及晨僵表现、实验室指标、关节症状的改善均具有确切优势，且不增加不良反应，值得临床应用。
Abstract:
Objective To investigate the clinical efficacy and safety of different doses of glucocorticoid in the treatment of rheumatoid arthritis (RA).Methods Sixty patients with RA admitted to Huangjiasi Hospital from January 2020 to February 2022 were selected and divided into high-dose group (30 cases) and low-dose group (30 cases) by random number table method. Both groups were treated with glucocorticoid (prednisone), the dose of high-dose group was 7.5-10 mg/d, and the dose of low-dose group was less than 7.5 mg/d. The pain assessment scale (RAPS) score, morning stiffness time, laboratory indexes [rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)], joint symptoms [number of tender joints, number of swollen joints, 28 joint disease activity score (DAS28)], clinical efficacy and adverse reactions were compared between the two groups.Results The RAPS score and morning stiffness time in the high-dose group were less than those in the low-dose group (P<0.05). The levels of RF, ESR and CRP in the high-dose group were lower than those in the low-dose group (P<0.05). The number of tender and swollen joints and DAS28 score in the high-dose group were less than those in the low-dose group (P<0.05). The clinical remission rate of the high-dose group was higher than that of the low-dose group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion High-dose (7.5-10 mg/d) glucocorticoid is more effective in the treatment of RA, which has definite advantages in improving pain and morning stiffness, laboratory indicators and joint symptoms, and does not increase adverse reactions. It is worthy of clinical application.

参考文献/References:

[1]刘欢,杨晓凌.老年类风湿性关节炎的临床特征及血清炎症因子的改变[J].实用临床医药杂志,2017,21(3):188-190.[2]王淼,代建宇.益赛普联合甲氨蝶呤治疗类风湿关节炎患者效果评价及对血清生化指标的影响[J].中国临床医生杂志,2017,45(6):74-76.[3]张婉.糖皮质激素联合抗风湿类药治疗类风湿关节炎54例临床研究[J].中国药业,2018,27(1):67-69.[4]马凤云,庞琳娜,孙聪慧.小剂量糖皮质激素联合甲氨蝶呤在类风湿关节炎达标治疗中应用及对患者血清TNF-a的影响[J].湖南师范大学学报(医学版),2018,15(1):28-30.[5]Santiago T,Voshaar M,de Wit M,et al.Patients’ and rheumatologists’ perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis-an international survey within the GLORIA study[J].Rheumatology (Oxford),2021,60(7):3334-3342.[6]中华医学会风湿病学分会.2018中国类风湿关节炎诊疗指南[J].中华内科杂志,2018,57(4):242-251.[7]Singh H,Arora S,Tanwar V,et al.The Validity and Sensitivity of Rheumatoid Arthritis Pain Scale on a Different Ethnic Group From Indian Rheumatoid Arthritis Patients[J].Arch Rheumatol,2019,35(1):90-96.[8]李爽,杨旭玲.小剂量糖皮质激素治疗对类风湿性关节炎患者基质金属蛋白酶3(MMP-3)水平的影响[J].实用药物与临床,2019,22(8):813-815.[9]冯秀媛,张芬燕,常志芳,等.类风湿关节炎患者骨质疏松与免疫调节性细胞因子的关系[J].中国临床研究,2020,33(2):154-157.[10]汤一榕,陈仁利,朱丽秀,等.甲氨蝶呤联合小剂量糖皮质激素治疗类风湿关节炎的疗效及对外周血中Tfh细胞和炎性因子的影响[J].贵州医药,2018,42(12):1414-1416.[11]Cutolo M,Paolino S,Gotelli E.Glucocorticoids in rheumatoid arthritis still on first line: the reasons[J].Expert Rev Clin Immunol,2021,17(5):417-420.[12]范薇,陈旭艳,赖飞,等.小剂量糖皮质激素联合艾拉莫德治疗早期活动性类风湿关节炎的临床研究[J].临床内科杂志,2019,36(9):618-620.[13]江珂,冯士广,路娜,等.小剂量泼尼松联合甲氨蝶呤对类风湿关节炎炎性细胞因子的影响[J].检验医学与临床,2017,14(11):1553-1555.[14]Sugihara T,Ishizaki T,Onoguchi W,et al.Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis:a 3-year prospective observational study[J].Rheumatology (Oxford),2021,60(9):4252-4261.[15]Corrado A,Rotondo C,Mele A,et al.Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis[J].Arthritis Res Ther,2021,23(1):180.[16]谷磊.抗环瓜氨酸多肽抗体与类风湿因子联合检测对类风湿关节炎的诊断价值[J].临床输血与检验,2017,19(6):611-613.[17]Mifsud KR,Saunderson EA,Spiers H,et al.Rapid Down-Regulation of Glucocorticoid Receptor Gene Expression in the Dentate Gyrus after Acute Stress in vivo: Role of DNA Methylation and MicroRNA Activity[J].Neuroendocrinology,2017,104(2):157-169.[18]Daskalakis NP,Meijer OC,de Kloet ER.Mineralocorticoid receptor and glucocorticoid receptor work alone and together in cell-type-specific manner: Implications for resilience prediction and targeted therapy[J].Neurobiol Stress,2022,18:100455.[19]黄小蝶,詹锋,吴智丹,等.类风湿性关节炎患者糖皮质激素用量及时间与肺部真菌感染发生的相关性研究[J].中华医院感染学杂志,2017,27(3):573-575,589.[20]程序,倪伟建,张圣雨.应用糖皮质激素对风湿免疫病患者骨密度的影响研究[J].安徽医药,2017,21(12):2326-2329.

相似文献/References:

[1]钟时嘉.亚急性甲状腺炎的临床分析[J].医学信息,2018,31(01):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
　ZHONG Shi-jia.Clinical Analysis of Subacute Thyroiditis[J].Journal of Medical Information,2018,31(08):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
[2]章 豫,艾艳红.蛋白质代谢变化、血脂与类风湿关节炎患者动脉粥样硬化的相关性研究[J].医学信息,2018,31(02):84.[doi:10.3969/j.issn.1006-1959.2018.02.028]
　ZHANG Yu,AI Yan-hong.Correlation between Changes of Protein Metabolism,Serum Lipids and Atherosclerosis in Patients with Rheumatoid Arthritis[J].Journal of Medical Information,2018,31(08):84.[doi:10.3969/j.issn.1006-1959.2018.02.028]
[3]唐培渊,宋俊峰,秦克乐,等.难治性特发性血小板减少性紫癜的治疗进展[J].医学信息,2018,31(05):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
　TANG Pei-yuan,SONG Jun-feng,QIN Ke-le,et al.Progress in Treatment of Refractory Idiopathic Thrombocytopenic Purpura[J].Journal of Medical Information,2018,31(08):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
[4]苗艳茹.甲巯咪唑与糖皮质激素联合治疗甲状腺功能亢进症合并症的效果分析[J].医学信息,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
　MIAO Yan-ru.Analysis of Effects of Methimazole and Glucocorticoids on Complications of Hyperthyroidism[J].Journal of Medical Information,2018,31(08):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
[5]康 凯,郑继伟,王 闰.糖皮质激素治疗甲亢伴浸润性突眼的疗效分析[J].医学信息,2018,31(08):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
　KANG Kai,ZHENG Ji-wei,WANG Run.Efficacy of Glucocorticoids in the Treatment of Hyperthyroidism with Infiltrating Exophthalmos[J].Journal of Medical Information,2018,31(08):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
[6]黄 娟,叶福银.类风湿关节炎合并腹痛1例[J].医学信息,2018,31(08):188.[doi:10.3969/j.issn.1006-1959.2018.08.070]
[7]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
　ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Journal of Medical Information,2018,31(08):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[8]刘广涛,关凤军,董 晨.原发性肾病综合征患儿肾组织P-gp170蛋白和mRNA表达与临床病理及预后的关系[J].医学信息,2018,31(21):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
　LIU Guang-tao,GUAN Feng-jun,DONG Chen.Relationship between the Expression of p-gp170 Protein and mRNA in Renal Tissue of Children with Primary Nephrotic Syndrome and Clinical Pathology and Prognosis[J].Journal of Medical Information,2018,31(08):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
[9]陈晓霞,唐 勇,胡 庆,等.吗替麦考酚酯联合糖皮质激素治疗特发性膜性肾病的疗效观察[J].医学信息,2018,31(22):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
　CHEN Xiao-xia,TANG Yong,HU Qing,et al.Therapeutic Effect of Mycophenolate Mofetil Combined with Glucocorticoid on Idiopathic Membranous Nephropathy[J].Journal of Medical Information,2018,31(08):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
[10]高 鹏,高 浩,燕 飞.坏疽性脓皮病1例[J].医学信息,2019,32(01):191.[doi:10.3969/j.issn.1006-1959.2019.01.063]

更新日期/Last Update: 1900-01-01